Pegcetacoplan (Syfovre™): targeting complement C3 in geographic atrophy

被引：0
|
作者：
Mastellos, Dimitrios C. [1 ]
Lambris, John D. [2 ]
机构：
[1] Natl Ctr Sci Res Demokritos, Athens, Greece
[2] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
来源：
TRENDS IN PHARMACOLOGICAL SCIENCES | 2024年 / 45卷 / 12期
关键词：
INHIBITION;
D O I：
10.1016/j.tips.2024.10.001
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1175 / 1176
页数：2
相关论文
共 50 条
  • [41] Targeting Hepatic Complement C3 Attenuates Pulmonary Arterial Hypertension Phenotype in Rodents
    Keles, Merve
    Arnold, Nadine
    West, Laura
    Turton, Helena
    Kim, Sung-Kwon
    Lasaro, Melissa
    Rammanujam, Meera
    Chang, Hong
    Wilkins, M.
    Lawrie, Allan
    CIRCULATION, 2024, 150
  • [42] Complement C3 mediated targeting of liposomes to granulocytic myeloid derived suppressor cells
    Kullberg, Max
    Martinson, Holly
    Mann, Kristine
    Anchordoquy, Thomas J.
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2015, 11 (06) : 1355 - 1363
  • [43] Complement inhibitors for the treatment of geographic atrophy
    Chew, Emily Y.
    LANCET, 2023, 402 (10411): : 1396 - 1398
  • [44] Complement Inhibitors for the Treatment of Geographic Atrophy
    Amin, Krisha V.
    Hariprasad, Seenu M.
    Danzig, Carl J.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2023, 54 (02): : 66 - +
  • [45] An AAV gene therapy for the treatment of geographic atrophy by targeting the alternative pathway of the complement system
    Joel, J.
    Tam, L.
    Dreisman, A.
    Stampoulis, D.
    Gardenal, E.
    Esteve-Rudd, J.
    Ellis, S.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A52 - A53
  • [46] Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions
    Kim, Benjamin J.
    Mastellos, Dimitrios C.
    Li, Yafeng
    Dunaief, Joshua L.
    Lambris, John D.
    PROGRESS IN RETINAL AND EYE RESEARCH, 2021, 83
  • [47] Efficacy and safety of intravitreal pegcetacoplan in geographic atrophy: Results from the phase 3 DERBY and OAKS trials
    Guymer, Robyn H.
    Mitchell, Paul
    Wong, James
    Heier, Jeff
    Singh, Rishi
    Steinle, Nathan
    Boyer, David
    Mones, Jordie
    Staurenghi, Giovanni
    Holz, Frank
    Bliss, Caleb
    Deschatelets, Pascal
    Grossi, Federico
    Francois, Cedric
    Wykoff, Charlie
    Ribeiro, Ramiro
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 49 (08): : 833 - 833
  • [48] Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases
    Dixon, Bradley P.
    Greenbaum, Larry A.
    Huang, Liwei
    Rajan, Sandeep
    Ke, Chunlei
    Zhang, Yiwei
    Li, Li
    KIDNEY INTERNATIONAL REPORTS, 2023, 8 (11): : 2284 - 2293
  • [49] The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis
    Garg, Anubhav
    Nanji, Keean
    Tai, Felicia
    Phillips, Mark
    Zeraatkar, Dena
    Garg, Sunir J.
    Sadda, SriniVas R.
    Kaiser, Peter K.
    Guymer, Robyn H.
    Sivaprasad, Sobha
    Wykoff, Charles C.
    Chaudhary, Varun
    SURVEY OF OPHTHALMOLOGY, 2024, 69 (03) : 349 - 361
  • [50] Extrahepatic secreted complement C3 contributes to circulating C3 levels in humans
    Naughton, MA
    Botto, M
    Carter, MJ
    Alexander, GJM
    Goldman, JM
    Walport, MJ
    JOURNAL OF IMMUNOLOGY, 1996, 156 (08): : 3051 - 3056
12345